MAPS plans to seek ap­proval of MD­MA-as­sist­ed ther­a­py this year af­ter sec­ond pos­i­tive PhI­II tri­al

MAPS Pub­lic Ben­e­fit Cor­po­ra­tion is tout­ing an­oth­er set of promis­ing Phase III re­sults in­ves­ti­gat­ing its MD­MA-as­sist­ed ther­a­py for post-trau­mat­ic stress dis­or­der (PTSD), with the tri­al hit­ting pri­ma­ry and sec­ondary end­points as the or­ga­ni­za­tion pre­pares for an NDA fil­ing this year.

The tri­al, MAPP2, is the sec­ond Phase III to con­firm pos­i­tive re­sults in pa­tients with PTSD.

Most of the par­tic­i­pants had a “sig­nif­i­cant re­duc­tion” in symp­toms of PTSD ver­sus those on place­bo who al­so re­ceived ther­a­py, earn­ing a p-val­ue of 0.001, with 86.5% ex­pe­ri­enc­ing a clin­i­cal­ly mean­ing­ful im­prove­ment at 18 weeks com­pared to 69.0% in the place­bo group.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER